Epitalon Sleep Architecture Impact: What the Clinical Evidence Shows

What the human studies measured

FDA's review identified three human studies of epitalon: two used a sublingual spray in night-shift workers, and one injected the peptide beside the eye in retinitis pigmentosa [1].

The night-shift study enrolled 75 healthy women aged 40 to 50, mostly shift workers. Forty had low melatonin output and were split into two groups of 20; they received a sublingual spray delivering about 0.5 mg per day, or placebo, for 20 days. Urinary 6-sulfatoxymelatonin rose about 1.7-fold on epitalon and did not change on placebo, and 83% versus 25% were described as improved in mood and physical condition [1]. The study was small and short, and blinding was not specified [1].

The 2002 retina study of epitalon injected beside the eye reported a 'positive clinical effect in 90% of the cases', with no sample sizes or design details in the abstract [5].

Why a melatonin metabolite is not sleep architecture

Sleep architecture means the stages recorded by polysomnography or EEG: time in N1, N2 and N3, REM latency and duration, and wake after sleep onset. The night-shift study recorded no sleep outcomes [1]. A rise in urinary 6-sulfatoxymelatonin shows a change in a urinary melatonin metabolite; it did not establish how epitalon changes melatonin in the body, which FDA says is unknown, or whether it changes sleep stages [1].

What FDA concluded about epitalon for insomnia

FDA evaluated only insomnia among the uses nominated for epitalon [1]. Its staff recommended against adding epitalon to the pharmacy bulk substances list, citing that the peptide is not well characterized, has no evidence of effectiveness for insomnia, has no clinical safety data, carries an immunogenicity concern for subcutaneous injection, and that many FDA-approved insomnia drugs exist [1]. On July 24, 2026 the Pharmacy Compounding Advisory Committee voted in favor of adding it, against that recommendation; the vote is advice only and epitalon is not on the list [2][3].

HHS filed a draft enforcement-discretion policy on October 28, 2026 covering epitalon acetate given by subcutaneous or intramuscular injection in intermittent courses [3][7]. The draft is not an approval, does not establish rights for any person, and does not put epitalon on an FDA list [3].

Safety and dosing

FDA found no clinical study that assessed epitalon's safety. Its adverse-event database search (through December 8, 2025) and food and supplement complaint system search (through December 5, 2025) retrieved no epitalon reports [1]. FDA warned that epitalon activates telomerase and lengthens telomeres, that longer telomeres are generally linked to higher cancer risk, and that it therefore has a mechanistic potential to be carcinogenic; the mouse cancer and chromosome-damage studies used a single fixed dose in female mice for a short exposure and were too limited to show safety [1]. FDA's page on bulk substances that may raise safety risks lists epitalon only in the table of substances nominated but withdrawn, and says injectable peptides may pose an immunogenicity risk from aggregation and impurities; removal from category 2 was not a finding that epitalon is safe [8]. There is no approved dose; the 5 to 10 mg daily cyclical regimens sold online are marketing, not evidence [1].